For the first time, ISCT will close out its Scientific Programming with a Keynote Address. Join us on the evening of Friday, May 9th, as Dr. Fred Appelbaum discusses the status of our sector and projects into its future.
In the late 1970s, Dr. Appelbaum led a research team that pioneered the use of autologous bone marrow transplantation, an approach that over the past thirty years has become a practical and accessible means of targeting several types of blood-based cancers.
He continues his work today in the treatment of blood cancers, as well as immune-based cancer treatments. He holds a leadership role at the Fred Hutch Cancer Center, where he contributes to setting the vision and standards for clinical research.
Dr. Appelbaum will close out the ISCT 2025 Scientific Program, speaking on the growth of our field and sharing his perspective into research developments that will impact the sector, contributing to the ISCT 2025 theme of Driving Global Innovation Towards Patient Access.